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Using clinical trial data and linked administrative
health data to reduce the risk of adverse events
associated with the uptake of newly released
drugs by older Australians: a model process
Margaret T Whitstock1*, Christopher M Pearce2, Stephen C Ridout3 and Elizabeth J Eckermann1
Abstract
Background: The study was undertaken to evaluate the contribution of a process which uses clinical trial data plus
linked de-identified administrative health data to forecast potential risk of adverse events associated with the use
of newly released drugs by older Australian patients.
Methods: The study uses publicly available data from the clinical trials of a newly released drug to ascertain which
patient age groups, gender, comorbidities and co-medications were excluded in the trials. It then uses linked de-
identified hospital morbidity and medications dispensing data to investigate the comorbidities and co-medications
of patients who suffer from the target morbidity of the new drug and who are the likely target population for the
drug. The clinical trial information and the linked morbidity and medication data are compared to assess which
patient groups could potentially be at risk of an adverse event associated with use of the new drug.
Results: Applying the model in a retrospective real-world scenario identified that the majority of the sample group
of Australian patients aged 65 years and over with the target morbidity of the newly released COX-2-selective
NSAID rofecoxib also suffered from a major morbidity excluded in the trials of that drug, indicating a substantial
potential risk of adverse events amongst those patients. This risk was borne out in post-release morbidity and
mortality associated with use of that drug.
Conclusions: Clinical trial data and linked administrative health data can together support a prospective
assessment of patient groups who could be at risk of an adverse event if they are prescribed a newly released
drug in the context of their age, gender, comorbidities and/or co-medications. Communication of this
independent risk information to prescribers has the potential to reduce adverse events in the period after the
release of the new drug, which is when the risk is greatest.
Note: The terms ‘adverse drug reaction’ and ‘adverse drug event’ have come to be used interchangeably in the
current literature. For consistency, the authors have chosen to use the wider term ‘adverse drug event’ (ADE).
1. Background
Coping with the outcomes of adverse drug events
(ADEs) associated with the use of newly approved
drugs, particularly in the elderly, has become a signifi-
cant problem in both primary care and hospital settings
in Australia, and is a major challenge for public health
policy worldwide. One in every ten Australian patients
who attend a GP in a primary care consultation has
experienced an ADE in the preceding six months, and
one in twenty has experienced a moderate to severe
ADE [1]. This translates to an estimated number of 2
million Australians who experience an ADE annually,
with 1 million of these ADEs classed as moderate or
severe, and 138,000 requiring hospitalisation [2]. ADEs
occur particularly in the elderly: adverse drug events
in people aged 60 years and over which had caused
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admission to, or an extended stay in, Western Austra-
lian hospitals between 1981-2002 increased more than
five-fold during that period [3].
Older patients are particularly vulnerable to adverse
drug events because of multiple-drug regimens and age-
associated changes in pharmacokinetics and pharmaco-
dynamics [4]. Privileging data from randomised con-
trolled clinical trials (RCTs) as the source of best
evidence to guide clinical decision-making may not well
serve the needs of the increasing number of patients in
older age groups, and may add to their problems rather
than ameliorating them.
Many older patients suffer from illnesses targeted by
newly approved drugs. However factors such as decreas-
ing physiological resilience, the follow-on effects of
cumulative morbidities, and effects of the increasing
numbers of medications taken to manage these morbid-
ities, together mean that the health profile of older
populations is moving further and further away from
the characteristics of the populations used in the clinical
trials. Despite this lack of fit, it is patients in older age
groups who are most frequently being prescribed new
drugs as soon as they are approved. The potential for
adverse drug events is greater when a new drug is pre-
scribed soon after its release onto the market, and rapid
uptake after release can place patients at risk of adverse
drug reactions and serious drug interactions through co-
prescribing [5].
A recent Australian medical journal editorial called for
the development of computerised systems that can deal
with the reality that only limited numbers of highly
selected patients are studied before a drug is approved for
marketing [2]. One such system could be an improved
pharmacovigilance system to detect ADE patterns asso-
ciated with a newly prescribed drug; however, identifying
the offending drug is not easy in a multi-morbidity/multi-
drug context, and pharmacovigilance systems also have an
inbuilt epistemological problem, as the reporting process
is subject to Type I and Type II errors [6].
Pharmacovigilance systems rely on spontaneous
reporting, and the large majority of adverse events are
either not recognised or not reported [7,8]. It has been
estimated by the FDA that the MedWatch system
receives only between 1% to 10% of adverse drug event
reports associated with any given drug [7-9]. Sponta-
neous reporting of adverse events has been described as
a particularly poor instrument for detecting increased
risks of common conditions such as cardiac disease
[10,11]. These common conditions are often those dis-
eases which become chronic in older age groups, and it
is persons in these age groups who are increasingly suf-
fering the effects of the impact of new drugs in the con-
text of old morbidities. A post-hoc approach to
identifying drug risks is too late for many older persons.
The Australian medical journal editorial referred to
above identified the need for a computerised system
that could focus on detecting early signals of potential
ADEs [2]. This paper presents a three-part risk identifi-
cation process that can be used to forecast which
patient groups could potentially be at risk of an ADE if
they are prescribed a newly released drug. If this process
is undertaken before any newly released drug is
approved for inclusion as a subsidised drug via Austra-
lia’s Pharmaceutical Benefits Scheme (PBS), this will
provide an opportunity to significantly reduce the num-
bers of persons who will need treatment for new-drug-
associated ADEs. Shifting costs away from responding
to preventable adverse health events and towards pre-
venting these adverse health events from occurring in
the first place is the preferable option for public health
expenditure.
2. Methods (Part 1)
This section addresses the generic methods underlying
the proposed risk identification model. The section
entitled Methods (Part 2) illustrates the application of
these methods in the case of the clinical trials of the
COX-2-selective NSAID rofecoxib and the patient
groups who would have been the main target population
for that arthritis drug.
2.1 Risk identification using clinical trial data
The first step uses data from reports of RCTs of a new
drug. The RCT study design relies on the exercise of a
range of controls to minimise bias, and this is done in
order to achieve the internal validity that is seen as a
scientific gold standard. However, internal validity is
often achieved at the expense of external validity. The
important issue of concern for older Australians taking
new drugs is that though more within-trial controls con-
tribute to an internally valid result, these controls fre-
quently involve the exclusion of potential participants
who have the very comorbidities and co-medications
that commonly exist in older age groups.
The RCT reports of a new drug are examined to iden-
tify whether there are age groups, gender, comorbidities
and/or co-medications recorded as having been
excluded from these clinical trials. Once exclusions are
applied in an RCT, for whatever reason, this removes
the possibility of gathering evidence on how the new
drug will act in patients who, for example, suffer from
one or more of the excluded morbidities, and/or who
take one or more of the excluded medications.
The examination of reports of clinical trials of new
drugs should take into consideration the scope of the
research questions posed, what data were sought, from
whom they were sought, what endpoints were adjudi-
cated, and what were the bases for outcome analyses. In
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this process, it is important to differentiate between
those exclusions which are specifically related to the
research questions being asked, and those exclusions
which relate to other body systems. For example, a clini-
cal trial of a new drug which is being evaluated for its
specific effects on gastric mucosa may have a protocol
that excludes persons already suffering from gastric
morbidities such as ulceration or bleeding. The exclu-
sion of patients with such gastric morbidities relates
specifically to the research question which seeks to eval-
uate the new drug in relation to its effects on gastric
mucosa. However, exclusion protocols relating to mor-
bidities in other body systems are applied for different
reasons, and can reduce the availability of important
knowledge about the action of the new drug in patients
who have those excluded morbidities.
Access to information on the clinical trials of a new
drug is via published research papers, but these may not
always be available, as sometimes they can be withheld
by the drug developer until after the drug is approved
for marketing. The Australian Therapeutics Goods
Administration (TGA) considers the results of Phase 1,
2 and 3 trials for a drug before it approves the registra-
tion of that drug for marketing in Australia. TGA
approval is also a pre-requisite for any drug to be con-
sidered for inclusion in the PBS schedules. The TGA
has recently commenced publishing an Australian Public
Assessment Report (AusPAR) on each drug that is
approved for marketing in Australia. These AusPAR
reports are a valuable source of information as they
include detailed summaries of the steps in the evalua-
tion process that led the TGA to approve or not
approve a prescription medicine submission. AusPARs
are modelled on the similar EPAR public assessment
report system implemented in the European Union [12].
Another significant source of RCT data is the U.S.
National Institutes of Health (NIH) website. Since 2007,
U.S. legislation has mandated that information about all
clinical trials that are commenced in the U.S. must be
made available on the NIH website with 2 months of
the enrolment of the first patient. The sponsor or devel-
oper of the new drug must submit to the NIH data
which include, inter alia, descriptive information, in
language intended for the lay public, concerning the
purpose of the trial, the study design, the disease or
condition being studied, the name of the drug, primary
and secondary outcome measures, eligibility criteria,
including exclusion protocols, and the trial protocol
identifier. The results of all clinical trials carried out in
the U.S. are required by law to be made available on the
NIH website within 30 days of the approval of a new
drug by the U.S. Food and Drug Administration (FDA).
These results must include data on participating patient
demographics, withdrawals and exclusions from the
final analysis, and tables of values for primary and sec-
ondary outcome measures, including statistical analyses
[13]. The NIH clinical trials database also includes
reports of clinical trials sponsored in other jurisdictions
when those trials have U.S. trial arms [14]. Some 50% of
the world’s new drugs are launched in the U.S. [15,16],
so the NIH website will be a comprehensive source of
detailed information on clinical trials of new drugs. At
the time of writing, the NIH website contains informa-
tion on 88,402 trials with locations in 172 countries.
The outcome of the first part of the model process is
a risk profile of patient groups whose ages, gender,
comorbidities and co-medications were not included in
the trial, and about whom there are effectively no data
on the potential action and potential effects of that new
drug.
2.2 Risk identification using Australian patient data
The second step uses de-identified administrative health
data to establish the age groups and gender of selected
subsets of current real-world Australian patients (e.g.
patients over 65 years of age) who have the morbidity
targeted by the new drug, and to establish what are the
comorbidities suffered by these patients and what are
the co-medications they are being prescribed. The pro-
cess uses morbidity data drawn from the diagnoses
fields of hospital separations records which have been
linked with medications data drawn from PBS pharma-
ceutical dispensing records.
Under a Memorandum of Understanding between the
Western Australian Department of Health and the
Commonwealth Department of Health and Ageing, the
W.A. Department of Health Data Linkage Unit has
established linkages between that State’s hospital separa-
tions records and the PBS dispensing records held by
the Commonwealth Department of Health and Ageing.
Using the linked data, it is possible to establish which
patient groups have the morbidity targeted by a new
drug (either via a hospital diagnosis and/or via one or
more medications dispensed), and then establish what
are the co-morbidities and co-medications associated
with these patients (again, either via hospital diagnosis
and/or medications dispensed). The result is a multi-
source health profile of patients with the morbidity of
interest.
Linked morbidity data can also be sourced from the
Commonwealth Department of Health and Ageing Med-
icare rebate data for approved consultations, procedures
and diagnostic services. Using these data would improve
and broaden the health profiling process. However, we
were looking for proof of the concept, and worked only
with two datasets described above.
Part of the remit of the newly formed Australian
Population Health Research Network is to link de-
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identified information from key administrative health
datasets across State, Territorial and Commonwealth
jurisdictions and health sectors to support population-
based research. The anticipated outcome benefits are
the capacity to improve the safety and quality of health
care, assess the effectiveness of preventive interventions,
enable longitudinal follow-up of research studies and sur-
veys, and monitor trends in the patterns and costs of
health care [17,18]. The authors suggest that development
of Australia-wide risk profiles for patient groups with the
target morbidities of newly released drugs could become
one of the responsibilities of this new body.
2.3 Risk identification comparing clinical trial data and
patient data
The third step is to take the comorbidity and co-medi-
cations risk profile developed from the examination of
exclusion protocols applied in RCTs of a new drug, and
compare it with the comorbidity and co-medications
risk profile developed from examination of the selected
subsets of current real-world Australian patients who
have the morbidity targeted by the new drug. Where
these two risk profiles differ, for example, when there is
one or more factors excluded in the clinical trials but
present in the real-world population, there is likely to be
limited information available about the action of the
new drug in those real-world patient groups. The output
of the comparison is a risk profile for the selected sub-
sets of current Australian patients who have the morbid-
ity targeted by a new drug, but who could potentially be
at risk of an adverse drug event if they are prescribed
that new drug in the context of their current age, gen-
der, comorbidities and/or co-medications. The final out-
put of the process is a warning advisory to be circulated
to prescribers warning of the lack of information on the
action of the new drug in the selected subsets of the
national population, and warning that if the drug is pre-
scribed, to closely monitor those patients to whom it is
prescribed.
When a new drug targets a morbidity experienced by
a large number of older patients, implementing the
model to assess potential risk should be a priority if the
drug is proposed for listing in the PBS schedules, as this
is usually the trigger for wide uptake.
3. Methods (Part 2)
This section presents a practical application of the gen-
eric methods outlined in Methods (Part 1). The data
analysed are from 14 clinical trials of the COX-2-selec-
tive NSAID rofecoxib, and the comorbidities and co-
medications of an arthritis patient cohort aged 65 years
and over in the State jurisdiction of Western Australia.
These patients formed part of the potential receiving
population for rofecoxib.
3.1 Risk identification using data from clinical trials of
rofecoxib
We analysed clinical trial data from 14 RCTs of the
COX-2-selective NSAID rofecoxib which were indicated
as being available in Australia before February 2001,
when rofecoxib was included in the PBS schedules
[19-22], which was the trigger for rapid uptake of the
drug across Australia. The 14 studies include eleven effi-
cacy trials, two safety trials, and one pooled study draw-
ing data from eight of the eleven efficacy trials [23-36].
The clinical trials of rofecoxib were checked for infor-
mation on the trial category (safety/efficacy), trial design,
aims and endpoints adjudicated, number of participants,
their age range and health status, excluded comorbid-
ities and co-medications, rofecoxib and comparator
dosage levels, trial durations, and patient withdrawals.
The principal focus was on the comorbidities and co-
medications which disqualified arthritis patients from
participation in the nine efficacy trials for patients with
osteoarthritis (OA) and the two efficacy trials for
patients with rheumatoid arthritis (RA).
Persons of both genders aged 65 years and over, the
age group of interest to us, were represented in the
RCTs analysed. We took into account that the COX-2-
selective NSAID rofecoxib was developed specifically to
relieve the pain and inflammation of arthritis without
the gastrointestinal morbidity associated with the use of
non-selective NSAIDS to treat arthritis inflammation.
As expected, there were consistent applications of gas-
tric morbidity exclusion protocols specifically related to
enabling the research questions to be asked. There were
also applications of exclusion protocols related to
enabling assessment of whether use of rofecoxib resulted
in improvement in arthritis symptoms. For example, in
an RCT evaluating rofecoxib for its specific effects on
improving pain on walking, exclusion protocols required
the capacity to walk for some measurable distance in
order to be able to evaluate improvement.
Of the exclusions relating to other body systems, we
also noted the exclusion of participants who had suf-
fered an unspecified active or recent hepatic disease. We
recognised that this exclusion was related to ensuring
the bioavailability of the new drug to be trialled. In ret-
rospect, it could have been of value to extract de-identi-
fied patient data on the level of occurrence of hepatic
disease in the over-65 age group with OA or RA. We
also noted the consistent exclusion of prospective parti-
cipants who had suffered one or more of a range of neo-
plastic events.
However, of exclusion protocols relating to other body
systems, what stood out in the examination of the
reports on the clinical trials of rofecoxib was the exclu-
sion of participants with vascular morbidities, and the
exclusion of participants who were taking vascular
Whitstock et al. BMC Public Health 2011, 11:361
http://www.biomedcentral.com/1471-2458/11/361
Page 4 of 11
medications. Patients with OA were excluded from par-
ticipation in the analysed RCTs of rofecoxib if one or
more of the following morbidities applied: adverse cardi-
ovascular factors (including Class III/IV angina or con-
gestive heart failure, controlled or uncontrolled
hypertension, or a requirement for anti-coagulant ther-
apy), adverse cerebrovascular factors (including a stroke
within 2 years prior, or a transient ischaemic event
within 2 years prior), or severe renal impairment (creati-
nine clearance ≤ 30 ml/min). Patients with RA were
excluded from participation in the analysed RCTs of rofe-
coxib if one or more of the following morbidities applied:
adverse cardiovascular factors (including a requirement
for anti-coagulant therapy, or a myocardial infarction
within 1 year prior), adverse cerebrovascular factors
(including a stroke within 2 years prior, or a transient
ischaemic attack within 2 years prior), or severe renal
impairment (creatinine clearance ≤ 30 ml/min).
Figure 1 presents the main comorbidity exclusion pro-
tocols applied in the efficacy clinical trials of rofecoxib,
grouped by arthritis type, and Figure 2 presents the vas-
cular co-medications exclusion protocols applied in the
efficacy clinical trials of rofecoxib, also grouped by
arthritis type.
This exclusion of patients being treated for cardiovas-
cular (CVD), cerebrovascular (CVA) or renal disease
meant that, as at February 2001, when rofecoxib was
made available through the PBS, there were effectively
no data available on the action of rofecoxib in patient
groups who were being treated for these morbidities. It
was this lack of data on the action of rofecoxib in the
presence of CVD, CVA and renal disease, as applied to
those arthritis patients in the 65 years and over age
group, that was of interest to the researchers.
3.2 Risk identification in an Australian arthritis patient
cohort
The real-world current patient groups we selected were
W.A. patients, male and female, who were aged 65 years
and over in 1999 and 2000, and who had either OA or
RA, the two major morbidities targeted by rofecoxib.
The presence of either OA or RA was to be established
based on de-identified PBS medications and hospital
RCT ID = Reference number in bibliography
OA = exclusion protocols for RCTs involving patients with osteoarthritis  
RA = exclusion protocols for RCTs involving patients with rheumatoid arthritis  
Number of Age range Mean age Duration of Cardiovascular Class III / IV Controlled or Past or present Myocardial Cerebrovascular History of stroke CVA event or
RCT ID patients of patients of patients clincial trial exclusions angina or CHF uncontrolled anticoagulant infarction / exclusions or stroke within TIA within
OA hypertension therapy coronary 2 years prior 2 years prior
Ref 24 784  40 years 63 years 52 weeks ¥ ¥ ¥ ¥ bypass ¥ ¥ ¥
Ref 26 809  40 years 64 years 6 weeks ¥ ¥ ¥ 1 year prior ¥ ¥ ¥
Ref 27 219  40 years 64 years 6 weeks ¥ ¥ ¥ ¥ ¥
Ref 28 672 38 - 92 yrs 62 years 6 weeks ¥ ¥ ¥ ¥ ¥
Ref 29 775 50 - 89 yrs 62 years 26 weeks ¥ ¥ ¥ ¥
Ref 30 742 47 - 87 yrs 62 years 26 weeks ¥ ¥ ¥ ¥
Ref 33 736 39 - 91 yrs 62 years 6 weeks ¥ ¥ ¥ ¥ ¥ ¥ ¥
Ref 34 693 38 - 85 yrs 62 years 52 weeks ¥ ¥ ¥ ¥ ¥ ¥ ¥
Ref 36 341 80 - 95 yrs 83 years 6 weeks ¥ ¥ ¥
RA
Ref 23 8076  40 years 58 years 32 wks (mean) ¥ ¥ ¥ ¥ ¥
Ref 35 658 24 - 86 yrs 55 years 8 weeks ¥ ¥
Protocols for the 7-day safety trial (Ref 32), the 2-week safety trial (Ref 25) and the pooled trial (Ref 31) are not included. The 9 RCTs in the pooled trial include 8 of the efficacy studies above.
Renal GI Hepatic Neoplastic
exclusions exclusions exclusions exclusions
Creatinine Active or Active or Recent  
clearance recent GI recent neoplastic  
RCT ID  30 ml/min ulceration, hepatic event
OA (severe RI) bleed,surgery disease  
Ref 24  ¥ ¥ ¥
Ref 26   ¥ ¥ ¥  
Ref 27  40 ml/min ¥ ¥ ¥
Ref 28   ¥ ¥ ¥ ¥
Ref 29   ¥ ¥ ¥
Ref 30   ¥ ¥ ¥
Ref 33   ¥ ¥ ¥ ¥
Ref 34   ¥ ¥ ¥ ¥
Ref 36   ¥ ¥ ¥
RA
Ref 23   ¥ ¥ ¥
Ref 35 ¥ ¥ ¥ ¥
Breakdown of cardiovascular exclusions Breakdown of CVA exclusions
Figure 1 Main comorbidity exclusion protocols applied in the efficacy clinical trials of rofecoxib, by arthritis type.
RCT ID = Reference number in bibliography
OA = exclusion protocols for RCTs involving patients with osteoarthritis 
RA = exclusion protocols for RCTs involving patients with rheumatoid arthritis 
Antithrombotic agents: Platelet Antithrombotic Other
RCT ID aggregation inhibitors excluding agents: Vitamin K
antagonists (unspecified)
Ref 24 Aspirin Ticlopodine hydrochloride Warfarin
Ref 26 Aspirin Ticlopodine hydrochloride Warfarin
Ref 27
Ref 28
Ref 29 Aspirin Ticlopodine hydrochloride Other anticoagulants
Ref 30 Aspirin Ticlopodine hydrochloride Other anticoagulants
Ref 33 Aspirin Ticlopodine hydrochloride Warfarin
Ref 34 Aspirin Ticlopodine hydrochloride Warfarin
Ref 36
RA
Ref 23 Aspirin Ticlopodine hydrochloride Other anticoagulants
Ref 35
Protocols for the 7-day safety trial (Ref 32), the 2-week safety trial (Ref 25) and the pooled
trial (Ref 31) are not included.
anticoagulants:
heparinOA
Figure 2 Vascular co-medication exclusion protocols applied in
the efficacy clinical trials of rofecoxib, by arthritis type.
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morbidity data, and co-morbidities and co-medications
data were to be established through links to the OA or
RA morbidity or medications data. The years 1999 and
2000 were chosen as arthritis patients in these two year
cohorts would have formed the potential target popula-
tion for rofecoxib.
The project was granted institutional ethics approval
by Deakin University, and this was accepted by the W.
A. Department of Health (W.A. DoH) and the Com-
monwealth Department of Health and Ageing (DoHA).
3.2.1 Medications data requested
Using the Australian Statistics on Medicine, we selected
a list of PBS Item Codes for high-use OA and RA medi-
cations dispensed in 1999 and 2000, and submitted the
list to DoHA through the W.A. DoH Data Linkage Unit
(DLU). We requested all PBS Item Codes linked to the
patients, male or female, aged 65 years and over, who
had been hospitalised with arthritis, as identified by a
selected list of ICD-9-CM and ICD-10-AM arthritis
diagnosis codes (see 3.2.2 below). We also requested
person-level PBS dispensing data for non-hospitalised
patients dispensed any of the selected high-use OA or
RA medications, together with any other co-medications
dispensed to these patients. We further requested data
on all medications that had been dispensed in the pre-
vious year to those patients in the Year 1999 and Year
2000 cohorts who had been prescribed the selected OA
or RA medications. Data supplied included age and gen-
der variables.
We received 1,370,073 PBS dispensing records defini-
tively linked to W.A. patients aged 65 years and over
who had been prescribed one or more of the selected
OA or RA medications in 1999, together with data on
any medications dispensed to these patients in 1998,
plus any PBS medications that had been dispensed to
W.A. patients aged 65 years and over who had an OA
or RA hospital diagnosis in 1999. We also received
1,817,455 PBS dispensing records definitively linked to
W.A. persons aged 65 years and over who had been pre-
scribed one or more of the selected OA or RA medica-
tions in the year 2000, together with data on any
medications dispensed to these patients in 1999, plus
any PBS medications dispensed to W.A. patients aged
65 years and over who had an OA or RA hospital diag-
nosis in 2000.
We also requested de-identified data for all the PBS
medications dispensed to any patients who were pre-
scribed rofecoxib between January 2003 and the end of
September 2004, when rofecoxib was withdrawn for
safety reasons, as we wished to examine what medica-
tions were being co-prescribed to patients who were
prescribed rofecoxib during this period. We received
3,561,701 PBS medications records for this analysis.
Though the medications data for the 1999 cohort were
analysed, this paper will report only on the detailed ana-
lyses of the medications data from the 2000 cohort, the
year prior to the inclusion of rofecoxib in the PBS sche-
dules. As noted in the key outcomes discussed in Section
5, there was a difference of only 1.5% between the year
1999 and the year 2000 medications analyses. The deci-
sion to restrict the 1999 medications reporting was linked
to issues associated with a change in ICD coding in that
year in Western Australia (see 3.2.2 below), as the final
cohort analyses for each year were designed to integrate
both medications and morbidity data.
Analysis of the January 2003 - September 2004 medi-
cations data is also addressed in Section 5.
3.2.2 Morbidity data requested
Using International Classification of Diseases (ICD)
manuals, we selected a list of ICD-9-CM arthritis codes
(for Jan-July 1999) and ICD-10-AM arthritis codes (July
1999 - Dec. 2000) which was submitted to the W.A.
DoH DLU. The extraction specifications requested per-
son-level hospitalisation morbidity data for all Year 1999
and Year 2000 patients, male or female, aged 65 years
or over whose hospital separation records included any
of the selected OA or RA ICD codes in either the pri-
mary diagnosis field or in any secondary diagnosis field.
We also requested hospital morbidity data from any
previous year’s hospitalisation for those 1999 and 2000
patients.
For the 1999 cohort, we received 27,580 hospital mor-
bidity records definitively linked to W.A. patients aged
65 years and over. These records included hospital mor-
bidity data from any patient hospitalisation episode in
1999, the previous year’s hospital morbidity data for any
1999 patient who had a hospitalisation episode in 1998,
plus 1999 hospital morbidity data linked to any patients
who had been dispensed a selected OA or RA medica-
tion in 1999. For the 2000 cohort, we received 34,269
hospital morbidity records definitively linked to W.A.
patients aged 65 years and over. These records included
hospital morbidity data from any patient hospitalisation
episode in 2000, the previous year’s hospital morbidity
data for any 2000 patient who had a hospitalisation epi-
sode in 1999, plus 2000 hospital morbidity data linked
to any patients who had been dispensed a selected OA
or RA medication in 2000.
On analysis, the 1999 data showed significant incon-
sistencies at the rollover from ICD-9-CM to ICD-
10-AM. The difference appears to be associated with a
greater frequency of application of secondary arthritis
diagnoses under ICD-9-CM, or a lower frequency of
application of secondary arthritis diagnoses under ICD-
10-AM. Given this inconsistency, we continued analysis
with morbidity data from the year 2000 only.
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4. Results
This section describes the analysis of the medication
and morbidity data to support the identification of
patients aged 65 years and over who would have poten-
tially been at risk if they had been prescribed rofecoxib.
It includes analyses of prescription medications
dispensed to this age cohort in 2000, and hospital-con-
firmed morbidities experienced by this age cohort in
2000.
4.1 Medications data analysis - 2000 cohort
The 1,817,455 dispensing records for the Year 2000
cohort were sorted into two groups: those for selected
OA and RA medications, and all other medications.
Using the Australian Statistics on Medicine, we selected
a list of high-use CVD medications dispensed in 2000,
and using this list we sorted all the non-OA/RA medica-
tions into three sub-groups: selected CVD medications,
all medications dispensed ≥3,000 times, and medications
dispensed <3,000 times. All medications dispensed
<3,000 times were not further considered.
There were 235,088 prescriptions dispensed for the
selected OA and RA medications, 514,756 prescriptions
dispensed for the selected CVD medications, and
653,793 prescriptions in the category of medications dis-
pensed ≥3,000 times.
Further analysis focused on the CVD medications
group, as CVD medications and morbidities were sub-
ject to exclusion protocols in the RCTs of rofecoxib
which were available prior to February 2001, when rofe-
coxib was included in the PBS schedules. All OA/RA
medications and CVD medications were analysed to
develop a person-level summary of these medications as
dispensed in 2000.
Of the 58,968 patients in the 2000 cohort aged 65
years and over who were prescribed OA/RA medica-
tions, 40,495 were co-prescribed CVD medications (see
Table 1). In the 2000 cohort, 68.8% of patients were
being medicated for both OA/RA and CVD.
Table 2 presents and age and gender breakdown of
the 18,373 patients taking OA/RA medications only and
the 40,595 patients who were co-prescribed OA/RA
medications plus CVD medications. The high percen-
tage (61%) of the 65-69 year age group co-prescribed
arthritis and cardiovascular medications would indicate
that the co-prescribing was already well established
in this Australian cohort by the age of 65, and that
cardiovascular disease was a significant morbidity for
many arthritis patients as they aged. The co-prescribing
of OA/RA and CVD medications compared with only
OA/RA medications increased steadily in all age groups.
These statistics suggest that the prescribing of a new
arthritis drug which consistently excluded persons with
cardiovascular disease from participating in its clinical
trials carries an elevation of risk if patients are moving
into the older age groups where it is evident that cardio-
vascular risk is increasing. The declining ratio of males
to females in the older age groups co-prescribed OA/RA
and CVD drugs suggest an additional elevation in cardi-
ovascular risk for males.
4.2 Morbidity data analysis - 2000 Cohort
The 34,269 Year 2000 hospital morbidity records
included data for 5,321 patients with an OA or RA diag-
nosis, and 28,948 patients with diagnoses for other mor-
bidities (see Table 3).
The age by sex breakdown of the 5,321 patients with
an OA or RA diagnosis is given in Table 4. The distri-
bution of male and female patients with hospital diag-
noses of OA/RA morbidity diverge from near-parity in
the 65-69 year age group to a 1:3 survival rate in the
85-99 age group. These statistics suggest that the pre-
scribing of a new arthritis drug which had consistently
excluded persons with cardiovascular disease from parti-
cipating in its clinical trials carries more risk for Austra-
lian male patients moving into the older age groups.
The 34,269 hospital morbidity records were then
merged with the 58,968 medications records patient
OA/RA medications records for the 2000 cohort merged
to support analyses of the common links. 44% of the
Australian patients over 65 years who suffered from
OA/RA diseases were treated with OA/RA medications
only; 4% of patients showed as having only a hospital
diagnosis of OA/RA, with no OA/RA medications (and
we surmise that these patients may be taking other
analgesics such as paracetamol or acetaminophen); 5%
of patients who were prescribed OA/RA medications
and also had an OA/RA hospital diagnosis; and 47% of
patients who were taking OA/RA medications suffered
had hospital diagnoses for one or more of cardiovascu-
lar, cerebrovascular and renal disease (see Table 5
below).
Table 6 reports on those patients in the 2000 Cohort
who were prescribed OA or RA medications and who
also had a hospitalisation event associated with a non-
OA/RA morbidity. Of the 58,968 patients taking an OA/
RA medication, there were 3,522 patients who had a
hospital CVD diagnosis; 666 patients taking an OA/RA
medication who also had a hospital CVA diagnosis; and
551 patients taking an OA/RA medication who also had
a hospital diagnosis of renal disease.
Table 1 2000 Cohort/Patient Medications
Drugs Prescribed No. of patients % of total
OA/RA drugs only 18,373 31%
OA/RA plus CVD drugs 40,595 69%
Total 58,968 100%
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A comparison of the number of Australian females
and males over 65 years who were taking OA/RA medi-
cations in the Year 2000 shows that males had signifi-
cantly higher levels of cardiovascular morbidity in the
65-69, 70-74 and 75-79 age groups, after which the data
reflect their relative reduced longevity compared with
females. This male/female pattern was repeated with
cerebrovascular disease and renal disease. However, the
major comorbidity for both sexes is clearly cardiovascu-
lar disease. The current morbidity patterns of the popu-
lation from which local patients were drawn would
suggest that the prescribing of a new arthritis drug
which had consistently excluded persons with cardiovas-
cular disease from participating in its clinical trials car-
ries an elevated risk for Australian patients over 65 with
OA/RA, with this risk being higher for male patients.
Table 7 reports on those patients in the 2000 Cohort
who were being treated in hospital for OA or RA who
were also treated in hospital for a non-OA/RA morbid-
ity. There were 966 patients treated in hospital for OA
or RA who were also being treated for CVD; 227
patients treated in hospital for OA or RA who were also
being treated for cerebrovascular disease; and 263
patients treated in hospital for OA or RA who were also
being treated for renal disease.
There were also 163 patients in the 2000 cohort who
were treated in hospital for OA or RA who were also
being treated for both CVD and CVA; 87 patients being
treated for OA or RA who were also being treated for
CVD and renal disease; and 13 patients being treated
for OA or RA who were also being treated for CVD,
CVA, and renal disease.
5. Discussion
From the reports of the efficacy RCTs of rofecoxib, it is
clear that the study design of these clinical trials signifi-
cantly curtailed the opportunities for patients with car-
diovascular, cerebrovascular and renal comorbidities to
be exposed to rofecoxib, and hence restricted the data
on the action of rofecoxib in these vascular morbidity
contexts.
From the linked de-identified administrative health
data for W.A. arthritis patients aged 65 years and over
in 2000, it is clear that CVD was a major comorbidity in
those patients, particularly in males, as identified in
both PBS medications data and hospital morbidity data.
In 2000, 68.8% of patients prescribed OA/RA medica-
tions were also prescribed CVD medications. The high
number of patients in the 2000 cohort who were diag-
nosed with CVD in hospital underscores this exposure.
Though the detailed analyses of the 1999 medications
data are not included in the paper, in that year, 67.3% of
patients prescribed OA/RA medications were also pre-
scribed CVD medications.
A pre-2001 analysis of available published clinical
trials of the OA/RA drug rofecoxib would have high-
lighted the limited participation of arthritis patients with
cardiovascular morbidity; and an examination of the
medications prescribed to real-world Australian OA/RA
patients aged over 65 years would have shown that
some 68% of these arthritis patients carried a cardiovas-
cular risk. Knowledge of these two factors alone could
Table 2 2000 Cohort / OA/RA vs. OA/RA + CVD medications, by age and sex
Age Group OA/RA
drugs only
Male
OA/RA
drugs only
Female
% of patients
taking OA/RA
drugs only
OA/RA plus
CVD drugs
Male
OA/RA plus
CVD drugs
Female
% of patients
taking OA/RA
plus CVD drugs
65-69 2,862 3,272 39% 4,427 5,255 61%
70-74 2,528 2,607 32% 4,999 6,035 68%
75-79 1,707 1,980 28% 4,091 5,535 72%
80-84 854 1,175 26% 2,159 3,648 74%
85-99 491 897 24% 1,327 3,119 76%
Sub-totals 8,442 9,931 17,003 23,592
Patient Total = 18,373 Patient Total = 40,595
Table 3 2000 Cohort/Hospital morbidities by morbidity
type
Morbidity No. of patients % of total
OA/RA morbidities 5,321 16%
Non-OA/RA morbidities 28,948 84%
Total 34,269 100%
Table 4 2000 Cohort/Patients with OA and RA
morbidities, by age, by sex
Age
Group
Total
numbers
with OA/RA
Sex
=
Male
Males as %
of age
group
Sex
=
Female
Females as %
of age
group
65-69 1,142 553 48% 589 52%
70-74 1,259 557 44% 702 56%
75-79 1,230 465 38% 765 62%
80-84 836 294 35% 542 65%
85-99 854 217 25% 637 75%
Total = 5,321 Total = 2,086 Total = 3,235
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have provided a clear caution concerning prescription of
rofecoxib for this arthritis patient group until more was
known about its effects in the context of CVD.
Other vascular morbidities, both cerebrovascular and
renal, were also evident in the patient population who
formed the potential receiving population for rofecoxib.
In hindsight, we know that the major problem with
rofecoxib was its capacity to precipitate or aggravate
CVD and CVA morbidity and mortality. Though the
risk of cardiovascular events was recognised by the FDA
as early as February 2001, this risk was not generally
known to prescribers due to the lack of adequate infor-
mation provided by the manufacturer.
To assess whether this could have been the case, we
checked all the medications data for persons dispensed
rofecoxib between January 2003 and September 2004
(when rofecoxib was withdrawn) to ascertain what other
medications were being taken by those persons during
that period. Of the 38,010 persons prescribed rofecoxib
in that period, 67% were also being co-prescribed medi-
cations to treat CVD, a potential indicator of a lack of
awareness of the link between cardiovascular risk and
use of the rofecoxib arthritis drug. Prior to its voluntary
safety withdrawal in September 2004, it has been esti-
mated that rofecoxib was implicated in more than a
thousand ADEs in Australian patients, of which about
30% resulted in deaths [37].
It is essential that there is a timely source of risk infor-
mation concerning new drugs, and this source must be
independent of the product information provided by the
new drug’s manufacturer, or by representatives of that
manufacturer who visit medical practices. Identification
of likely or possible risk should be undertaken before
there is the opportunity for a problem to be realised.
Had we assembled all the relevant information we
now know to have been available in Australia before the
PBS listing of rofecoxib, we could have identified the
discrepancies between the profile of the OA/RA patients
included in the analysed rofecoxib RCTs and the profile
of the local OA/RA patient groups aged 65 years and
over. The restriction of cardiovascular, cerebrovascular
and renal disease exposure in rofecoxib trial patients,
and the limitation of cardiovascular adjudication in
most of the analysed RCTs, could together have served
to indicate a significant shortfall in knowledge about the
action and effects of rofecoxib in those disease contexts,
and pointed to the potential risk of ADEs in patients
with these diseases if they were to be prescribed the
drug. These patients could then have been advised to
take a different NSAID, paracetamol, or other treatment
option. The rofecoxib-associated morbidity and mortal-
ity adverse events in Australian patients could have
been reduced using data that was available before they
occurred.
6. Conclusion
Implementing the model process described in this paper
before a newly released drug is included in Australian
PBS schedules could support production of a profile of
patient groups potentially at risk of an ADE if pre-
scribed that new drug in the context of their age, gen-
der, comorbidities and/or co-medications. This risk
Table 5 2000 Cohort/Merged OA/RA medications and hospital morbidity data
Total number of patients 61,139 % of total
Patients with OA/RA medications only 26,870 44%
Patients with OA/RA morbidities only 2,171 4%
Patients with OA/RA medications linked to OA/RA morbidities 3,150 5%
Patients with OA/RA medications linked to non-OA/RA morbidities 28,948 47%
100%
Table 6 2000 Cohort/Patients on OA/RA medications who also had CVD, CVA or renal morbidity, by age and sex
OA/RA drugs plus
cardiovascular
disease
Male
vs.
Female
OA/RA drugs plus
cerebrovascular
disease
Male
vs.
Female
OA/RA drugs plus
renal disease
Male
vs.
Female
Age Group Male Female % Male Female % Male Female %
65-69 356 203 64 : 36 49 32 60 : 40 32 27 54 : 46
70-74 488 303 62 : 38 77 47 62 : 38 62 29 68 : 32
75-79 445 379 54 : 46 84 83 50 : 50 76 45 63 : 37
80-84 327 327 50 : 50 78 85 48 : 52 66 54 55 : 45
85-99 244 450 35 : 65 44 87 34 : 66 71 89 44 : 56
Sub-totals 1,860 1,662 332 334 307 244
Patients = 3,522 Patients = 666 Patients = 551
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information could then be communicated to prescribers,
and would serve to promote caution until more is known
about that new drug. This, in turn, would have the poten-
tial to reduce ADEs at the time when the risk is greatest.
Prospective identification of risk would make a valu-
able contribution to the health of the increasing num-
bers of older patients with multiple morbidities who
are being co-prescribed new drugs soon after they are
released.
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